Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gastrointestinal 2Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 42Carcinoma, Non-Small-Cell Lung 18Neoplasms 15Neoplasm Metastasis 14Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 8Ovarian Neoplasms 6Colorectal Neoplasms 6Uveal Melanoma 5Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Pancreatic Neoplasms 5Mesothelioma 5Diabetes Mellitus, Insulin-Dependent, 12 5Carcinoma, Transitional Cell 5Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Lung Neoplasms 4Carcinoma, Merkel Cell 4Advanced Cancer 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Prostatic Neoplasms 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Liver Neoplasms 3Hodgkin Disease 3Head and Neck Neoplasms 3Carcinoma 3

Interventions

Pemetrexed 7Cisplatin 7Cyclophosphamide 5pembrolizumab 4fludarabine 4Platinum 3Drug Therapy 3aldesleukin 2Nivolumab 2Ipilimumab 2Interleukin-2 21,2-diaminocyclohexaneplatinum II citrate 2vatalanib 1spartalizumab 1regorafenib 1napabucasin 1methoxyamine 1fludarabine phosphate 1enzalutamide 1cediranib 1avelumab 1atezolizumab 1anetumab ravtansine 1Vorinostat 1Thiostrepton 1Tetrahydrouridine 1Radiosurgery 1Megestrol Acetate 1Levoleucovorin 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Mesothelioma, Malignant × Ipilimumab × Clear all
NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

Phase 1/2 Recruiting
126 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
57 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡